eli lilly glp-1 products Why is suddenly pulling ahead in the weight-loss race Novo Nordisk sues Eli Lilly

By delaying the movement of food from the stomach into the small intestine, GLP-1 medications can affect how the gastrointestinal tract functions during the critical post-operative recovery period

Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies

A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice

doi:10.3945/ajcn.2009.28449C 10

Reasons for low levels of initiation and long-term use of AOMs may include reluctance of public health and medical organizations to recognize obesity as a disease, lack of reimbursement, provider inexperience, and misperceptions about the efficacy and safety of available treatments